Drug therapy for obesity: An update

Journal of the American Pharmaceutical Association

Volumn 37, Issue 1, 1997, Pages

  Popovich, N G ^a   Wood, O B ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEPRAMONE; AMINOPHYLLINE; AMPHETAMINE; ANOREXIGENIC AGENT; BENZPHETAMINE; CHROMIUM PICOLINATE; DEXFENFLURAMINE; EMETINE; FENFLURAMINE; FLUOXETINE; LEPTIN; MANNAN; MAZINDOL; METHAMPHETAMINE; PHENDIMETRAZINE TARTRATE; PHENMETRAZINE; PHENTERMINE; PHENTERMINE RESIN; PHENYLPROPANOLAMINE; PROLAMIN; SEROTONIN AGONIST; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; ANTIOBESITY AGENT; NEW DRUG; NON PRESCRIPTION DRUG;

ARTICLE; BODY MASS; CARDIOTOXICITY; DIARRHEA; DIET; DRUG CHOICE; DRUG EFFICACY; DRUG INFORMATION; HUMAN; HYPERTENSION; INSOMNIA; NEUROTOXICITY; OBESITY; PATIENT EDUCATION; SIDE EFFECT; COMPARATIVE STUDY; PRESCRIPTION; REVIEW;

ANTI-OBESITY AGENTS; DRUGS, INVESTIGATIONAL; DRUGS, NON-PRESCRIPTION; HUMANS; OBESITY; PRESCRIPTIONS, DRUG;

EID: 0031053216     PISSN: 10865802     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1086-5802(16)30175-9     Document Type: Article

References (34)

1. A. Frank Futility and avoidance. Medical professionals in the treatment of obesity JAMA 269 1993 2132 2133 Commentary.
2. S.Z. Yanovski Are anorectic agents the 'magic bullet' for obesity? Arch Fam Med. 2 1993 1025 1027
3. S.L. Gortmaker A. Must J.M. Perrin Social and economic consequences of overweight in adolescence and young adulthood N Engl J Med. 329 1993 1008 1012
4. Committee to Develop Criteria for Evaluating the Outcome of Approaches to Prevent and Treat Obesity P.R. Thomas Weighing the Optians. Criteria far Evaluating Weight-Management Programs 1995 National Academy Press Washington, D.C
5. G.A. Bray Use and abuse of appetite-suppressant drugs in the treatment of obesity Ann Intern Med. 119 1993 707 713
6. G.A. Bray The obese patient WB Saunders Company 1976 1 450
7. A.S. Levy A.W. Heaton Weight control practices of U.S. adults trying to lose weight Ann Intern Med 119 1993 661 666
8. K.A. Stahl T.F. Imperiale An overview of the efficacy and safety of fenfluramine and mazindol in the treatment of obesity Arch Fam Med. 2 1993 1033 1037
9. M. Weintraub P.R. Sundaresan M. Madan Long-term weight control study I (weeks 0 to 34) Clin Pharmacal Ther. 51 1992 586 594
10. M. Weintraub P.R. Sundaresan B. Schuster Long-term weight control study II (weeks 34 to 104) Clin Pharmacal Ther. 51 1992 595 601
11. M. Weintraub P.R. Sundaresan B. Schuster Long-term weight control study III (weeks 104-156) Clin Pharmacal Ther. 51 1992 602 607
12. M. Weintraub P.R. Sundaresan B. Schuster Long-term weight control study IV (weeks 156to 190) Clin Pharmacal Ther. 51 1992 608 614
13. M. Weintraub P.R. Sundaresan B. Schuster Long-term weight control study V (weeks 190 to 210) Clin Pharmacol Ther. 51 1992 615 618
14. M. Weintraub P.R. Sundaresan C. Cox Long-term weight control study VI Clin Pharmacal Ther. 51 1992 619 633
15. M. Weintraub P.R. Sundaresan B. Schuster Long-term weight control study VII (weeks 0 to 210) Clin Pharmacal Ther. 51 1992 634 641
16. M. Weintraub Long-term weight control study: Conclusions Clin Pharmacal Ther. 51 1992 642 646
17. B.R. Olin Facts and Camparisons 1996 St. Louis Facts and Comparisons editor-in-chief
18. H.M. Pouwels J.L. Smeets E.C. Cherlex Pulmonary hypertension and fenfluramine Eur Respir J. 3 1990 606 607
19. J. McMurray P. Bloomfield H.C. Miller Irreversible pulmonary hypertension after treatment with fenfluramine BMJ. 292 1986 239 240
20. L. Abenhaim Y. Moride F. Brenot Appetite-suppressant drugs and the risk of primary pulmonary hypertension New Engl J Med. 335 1996 609 616
21. O.B. Wood N.G. Popovich Nonpharmacologic treatment of obesity J Am Pharm Assoc. NS36 1996 636 650
22. K. Rodgers Girth control Drug Topics 140 10 1996 30
23. P.L. Doering Weight Control Products T.R. Covington Handbook of Nonprescription Drugs 11th ed. 1996 American Pharmaceutical Association Washington, D.C.
24. S. Algers K. Larsen V.L. Boyce Effect of phenylpropanolamine on energy expenditure and weight loss in overweight women Am J Clin Nutr. 57 1993 120
25. F.L. Greenway Clinical studies with phenylpropanolamine: a metanalysis Am J Clin Nutr. 55 1993 203S
26. L.V. Allen Jr. Aminophylline Cream US Pharmacist 18 12 1993 106 107
27. USP Dispensing Information. Volume I. Drug Information for the Health Care Professional 15th ed 1995 United States Phar-macopeial Convention, Inc Rockville, Md
28. K.N. Jeejeebhoy R.C. Chu E.B. Marliss Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation in a patient receiving long-term total parenteral nutrition Am J Clin Nutr. 30 1977 531 538
29. F.J. Friedman Death from ipecac intoxication in a patient with anorexia nervosa Am J Psychiatry. 141 1984 702
30. W.D. Robertson Syrup of ipecac associated fatality: a case report Vit Hum Toxicol. 21 1979 87
31. G.A. Bray D.H. Ryan D. Gordon A double-blind randomized placebo-controlled trial with sibutramine Obesity Res. 4 1996 263 270
32. Keeping up (September 1996) B.R. Olin Facts and Comparisons 1996 Facts and Comparisons St. Louis editor-in-chief.
33. M.D. Turton D. O'Shea I. Gunn A role for glucagon-like peptide-1 in the central regulation of feeding Nature. 379 1996 69
34. Robison Jl S.L. Hoerr K.A. Petersmarck J.V. Anderson Redefining success in obesity intervention: The new paradigm J Am Diet Assoc. 95 1995 422 423